Close Menu

NEW YORK - Swiss firm Novigenix said today that it is collaborating with radiopharmaceutical company RadioMedix to develop a precision oncology diagnostic for patients with neuroendocrine tumors. 

Under the agreement, Novigenix will create an immune-transcriptomic-based test using its proprietary LITOseek platform to monitor the effectiveness of a type of treatment, alpha and beta peptide receptor radionuclide therapy (PRRT), which RadioMedix is developing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.